BridgeMD
New treatment option for Cystic Tumors of the Sellar/Parasellar Region
Official title 90Yttrium Colloid for the Treatment of Cystic Sellar/Parasellar Tumors
ClinicalTrials.gov ID: NCT02081768
What this study is testing
- What it's testing
- There is no consensus in the literature on the best way to treat cystic lesions of the pituitary area. Patients who are symptomatic from these tumours are rare.
- Phase 3: a large, late-stage study
- Time commitment: about 10 years
A plain-language read of the study's public ClinicalTrials.gov listing. The study team confirms the details.
Who can take part
Ages 17 and older
You may be able to join if
- Criteria Ages Eligible for Study: 17 years of age or older Genders Eligible for Study: Both Accepts Healthy Volunteers: No Patients who meet all of...
- Patients 17 years of age or older.
- Cystic sellar, suprasellar, parasellar or intrasellar masses diagnosed by histology, cytology or neuroimaging.
- Tumour measurements and/or tumour volume can be calculated.
- Patients who require surgical intervention as determined by the treating neurosurgeon.
You likely can't join if
- Patients who meet any of these criteria are not eligible for enrollment as study participants:
- Neurosurgeon's assessment that surgical procedures hold unacceptable operative risk.
- Having a solid tumour.
- Pregnant or breast feeding at time of surgical consent and/or surgery.
- Hypersensitivity, allergies or contraindication to the used radiopharmaceutical agent (90yttrium colloid).
See the full eligibility criteria
- Criteria Ages Eligible for Study: 17 years of age or older Genders Eligible for Study: Both Accepts Healthy Volunteers: No Patients who meet all of the following criteria are eligible for enrollment as study...
- Patients 17 years of age or older.
- Cystic sellar, suprasellar, parasellar or intrasellar masses diagnosed by histology, cytology or neuroimaging.
- Tumour measurements and/or tumour volume can be calculated.
- Patients who require surgical intervention as determined by the treating neurosurgeon.
- Being a patient managed in the Halifax Neuropituitary Program surgical clinic.
- Willingness to undergo surgery and give informed surgical consent.
- Willingness to provide informed consent for study participation.
- Patients who meet any of these criteria are not eligible for enrollment as study participants:
- Neurosurgeon's assessment that surgical procedures hold unacceptable operative risk.
- Having a solid tumour.
- Pregnant or breast feeding at time of surgical consent and/or surgery.
- Hypersensitivity, allergies or contraindication to the used radiopharmaceutical agent (90yttrium colloid).
The study team makes the final eligibility decision.
Where it's taking place
- Halifax, Nova Scotia, Canada
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The study runs about 10 years per participant, based on its public description. The team confirms the exact schedule and number of visits before you enroll.
Who can join this trial?
This study is enrolling all sexes, 17 years and older. The study team makes the final eligibility decision.
Where is this trial taking place?
Study sites include Halifax, Nova Scotia, Canada. Enter your location above to see the nearest site and check your eligibility.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from ClinicalTrials.gov; the study team decides eligibility.